Cholesterol content of cells must be maintained within the very tight limits, too much or too little cholesterol in a cell results in disruption of cellular membranes, apoptosis and necrosis 1
The cholesterol efflux assay is designed to quantitate the rate of cholesterol efflux from cultured cells. It measures the capacity of cells to maintain cholesterol efflux and/or the capacity of plasma acceptors to accept cholesterol released from cells. The assay consists of the following steps.
Step 1: labelling cellular cholesterol by adding labelled cholesterol to serum-containing medium and incubating with cells for 24-48 h. This step may be combined with loading of cells with cholesterol.
Step 2: incubation of cells in serum-free medium to equilibrate labelled cholesterol among all intracellular cholesterol pools. This stage may be combined with activation of cellular cholesterol transporters.
Step 3: incubation of cells with extracellular acceptor and quantitation of movement of labelled cholesterol from cells to the acceptor. If cholesterol precursors were used to label newly synthesized cholesterol, a fourth step, purification of cholesterol, may be required.
The assay delivers the following information: (i) how a particular treatment (a mutation, a knock-down, an overexpression or a treatment) affects the capacity of cell to efflux cholesterol and (ii) how the capacity of plasma acceptors to accept cholesterol is affected by a disease or a treatment. This method is often used in context of cardiovascular research, metabolic and neurodegenerative disorders, infectious and reproductive diseases. 
Video Link

Plating Cells and Labelling Cellular Cholesterol
This protocol has been tested using the following cell types: human monocytes 4, 5 ,THP-1 human monocyte-macrophages 6, 7, 8 , RAW 264.7 murine macrophages 5, 9, 10, 11 , HeLa cells 12 , human umbilical vein endothelial cells (HUVEC), BHK-21 cells 9 , human and mouse fibroblasts 13, 14 , HepG2 human hepatocarcinoma cells 15 and, in modified form, from platelets 16 .
1. Resuspend cells and count them. Plate cells into 12-well plates at the final density of 0.2x10 6 cells per well in 0.9 ml complete medium.
Cells will continue growing and will reach 0. 
Analysing the Results
1. The rate of cholesterol efflux is usually expressed as a proportion of cholesterol moved from cells to the acceptor. The following formula is used:
2. The specific efflux is calculated as a difference between the efflux in the presence or absence of the acceptor (blank).
Timeline
Representative Results
An example of an outcome of a cholesterol efflux experiment is shown in Fig. 1 . In this experiment THP-1 human monocytes were differentiated into macrophages and cholesterol efflux to different acceptors was tested. Cholesterol efflux to medium with no acceptors ("blank") was 0.79% and this value was regarded as a non-specific efflux and was subtracted from other values. Cholesterol efflux to human apoA-I (final concentration 30 μg/ml) was 4.75%. A reference plasma sample was included into this experiment to monitor inter-experimental variability. A reference sample can be used for normalization of data across a large number of experiments, but we found it prudent to repeat the assay if variability is high. A patient plasma (final concentration 2%) was tested before and after the patient was treated with medication. It was concluded that in this patient medication had a negative impact on the capacity of plasma to support cholesterol efflux.
Another example of an outcome of the efflux experiment is shown in Fig. 2 . In this experiment RAW 264.7 macrophages were activated or not activated by overnight incubation with LXR agonist TO-901317 (final concentration 1 μmol/L) and cholesterol efflux to the same sample of human plasma (2%) was tested. It was concluded that activation of cellular expression of ABC transporters with LXR agonist increases the capacity of cells to release cholesterol to extracellular acceptor. 
Discussion
The described method to measure cholesterol efflux is designed to measure movement of cholesterol from cells to an extracellular cholesterol acceptor. There are several critical considerations in understanding this methodology.
Labelling and equilibration
In the described methodology labelled cholesterol is added to serum-containing serum. Although never investigated in detail, it is assumed that cholesterol is incorporated into serum lipoproteins and they are taken up by cells. It is important to allow sufficient time for lipoproteins to be taken up and for cholesterol to move from lipoproteins to cellular membranes. Usually 24 h labelling is sufficient, but labelling for 48 h achieves higher specific activity of intracellular cholesterol. It needs to be taken into account that if [
